Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.

[1]  G. M. Sperandio da Silva,et al.  Safety of benznidazole use in the treatment of chronic Chagas' disease. , 2012, The Journal of antimicrobial chemotherapy.

[2]  R. López-Vélez,et al.  Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment , 2012, Current Infectious Disease Reports.

[3]  J. Coura,et al.  Chronic phase of Chagas disease: why should it be treated? A comprehensive review. , 2011, Memorias do Instituto Oswaldo Cruz.

[4]  R. López-Vélez,et al.  Chagas disease in Latin American migrants: a Spanish challenge. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  C. Combescure,et al.  Tolerance and safety of nifurtimox in patients with chronic chagas disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Gascón,et al.  Tolerance of Benznidazole in Treatment of Chagas' Disease in Adults , 2010, Antimicrobial Agents and Chemotherapy.

[7]  Z. Yadón,et al.  Chagas disease: a Latin American health problem becoming a world health problem. , 2010, Acta tropica.

[8]  S. Wilkinson,et al.  Trypanocidal drugs: mechanisms, resistance and new targets , 2009, Expert Reviews in Molecular Medicine.

[9]  O. Yun,et al.  Feasibility, Drug Safety, and Effectiveness of Etiological Treatment Programs for Chagas Disease in Honduras, Guatemala, and Bolivia: 10-Year Experience of Médecins Sans Frontières , 2009, PLoS neglected tropical diseases.

[10]  M. G. Álvarez,et al.  Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities , 2009, Expert review of anti-infective therapy.

[11]  Robert H Gilman,et al.  Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.

[12]  Ginés Sanz,et al.  Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica , 2007 .

[13]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[14]  A. Rassi,et al.  [Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid]. , 2002, Revista da Sociedade Brasileira de Medicina Tropical.

[15]  M. Montera,et al.  I Diretriz Latino-Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica , 2011 .

[16]  J. Marin-Neto,et al.  [I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy]. , 2011, Arquivos brasileiros de cardiologia.

[17]  G. Sanz,et al.  [Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic]. , 2008, Enfermedades infecciosas y microbiologia clinica.

[18]  W. Ziegler,et al.  Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. , 1979, Arzneimittel-Forschung.